MedTrace Logo

Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients

NCT07321613 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 545

Last updated 2026-01-07

No results posted yet for this study

Summary

This is a multicenter, retrospective cohort study that aims to evaluate the efficacy and safety of a triple-drug cocktail (TCC), consisting of Thalidomide, Carmofur, and Compound Mylabris Capsules (CMC), in combination with conventional Transarterial Chemoembolization (TACE) for the treatment of patients with unresectable Hepatocellular Carcinoma (HCC).

Conditions

  • Hepatocellular Cancer (HCC)

Interventions

PROCEDURE

TACE

received initial treatment with traditional TACE by well-trained and experienced physicians

DRUG

carmofur

carmofur tablets (Qilu Pharmaceutical, 100 mg, tid)

DRUG

compound mylabris capsule

CMC (Guizhou Yibai Pharmaceutical Co., Ltd, 750 mg, bid)

DRUG

Thalidomide (50mg)

Thalidomide tablets (Changzhou Pharmaceutical Factory, 50 mg qn)

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2025-05-01
Completion
2025-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07321613 on ClinicalTrials.gov